DYDan Yang

Dan Yang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Dan Yang has a total of 23 co-authors. Here are the top co-authors by number of shared publications:

  • Bingjia Zhao

    Department of Traditional Chinese Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China

    2 shared publications
  • Yanfei Che

    Department of Traditional Chinese Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China

    2 shared publications
  • Ziman Yu

    Department of Traditional Chinese Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China

    2 shared publications
  • Dongshan Qin

    Department of Traditional Chinese Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China

    1 shared publication
  • Guoxi Zhang

    Nanjing Luye Pharmaceutical Co., Ltd, Nanjing, 210061, Jiangsu, China

    1 shared publication
  • Hangqi Liu

    Department of Pathology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China

    1 shared publication

Latest Publications

  • Top Cited Papers
    Open Access

    Decoding TREM2 Signaling Pathways

    by Yanfei Che, Ziman Yu, Songjie Ji, Dan Yang

    Triggering receptor expressed on myeloid cells 2 (TREM2) is a key immunomodulatory receptor broadly expressed on myeloid cells such as macrophages and microglia. It plays versatile roles in neurodegenerative diseases, tissue repair, and tumor immunity by orchestrating glucose metabolism and inflammatory responses. This review systematically summarizes the structural characteristics of TREM2, its ligand-binding mechanisms, and downstream signaling pathways-including the phosphoinositide 3-kinase/protein kinase B(PI3K/Akt), mitogen-activated protein kinase (MAPK), nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB), and signal transducer and activator of transcription 3 (STAT3) cascades-with a particular focus on its central role in macrophage metabolic reprogramming.In neurodegenerative diseases such as Alzheimer disease, TREM2 contributes to the attenuation of neuroinflammation and slows disease progression by promoting β-amyloid (Aβ) clearance, inhibiting tau hyperphosphorylation, and modulating microglial polarization. Loss-of-function sequence variants, such as R47H, disrupt lipid metabolism, impair phagocytic activity, and destabilize immune homeostasis, thereby significantly increasing disease susceptibility. Furthermore, by enhancing glycolysis and suppressing fatty acid oxidation, TREM2 facilitates macrophage polarization toward a reparative M2 phenotype, promoting neuroregeneration and remyelination in conditions such as spinal cord injury and multiple sclerosis.Within the tumor microenvironment, TREM2 influences tumor progression and therapeutic resistance by modulating the metabolic reprogramming of tumor-associated macrophages (TAMs)-notably through activation of pyruvate kinase muscle isozyme M2 (PKM2)-dependent glycolysis-and promoting an immunosuppressive phenotype. In metabolic disorders such as diabetes and obesity, TREM2 exerts protective effects by inhibiting NLRP3 inflammasome activation and maintaining lipid homeostasis, highlighting its therapeutic potential.This review also outlines the translational prospects of TREM2 as a therapeutic target, including the development of agonists, gene regulatory strategies, and its potential use as a biomarker. Future studies should aim to elucidate the ligand-specific biased signaling and dynamic regulatory networks of TREM2 within tissue microenvironments to advance precision interventions in neuroimmunometabolic diseases.


  • Open Access

    Elucidation of the mechanism of Jinmaitong against Diabetic peripheral neuropathy based on a combined strategy of network pharmacology and molecular biology

    by Ziman Yu, Bingjia Zhao, Wei Song, Hangqi Liu, Yanfei Che, Dongshan Qin, Xiaochun Liang, Dan Yang

    Background: Diabetic peripheral neuropathy (DPN) is a common complication of type 2 diabetes mellitus (T2DM) with limited treatment options. The traditional Chinese medicine Jinmaitong (JMT) has demonstrated efficacy in treating DPN in both clinical and animal studies. It is worth noting that macrophage polarization appears to play a significant role in the onset and progression of DPN. However, whether the specific mechanism by which JMT exerts its neuroprotective effects is related to macrophage polarization still requires further in-depth investigation. Methods: T2DM model was established using Sprague–Dawley (SD) rats induced by a high-fat diet for six weeks combined with streptozotocin (STZ) injection. After modeling and drug administration, the DPN status was assessed using the von Frey test to test mechanical threshold, the hot plate test and tail flick test to evaluate thermal response latency, and the bioelectric amplifier to measure motor nerve conduction velocity. In the first batch of in-vivo experiments (Batch 1), after establishing the type 2 diabetes model, we conducted herbal formula JMT administered daily via oral gavage for another four weeks, eight weeks or twelve weeks, with each study comprising four groups: control group (CON), DPN group (DPN), low-dose JMT (7.6 mg/kg) treated group (DPN + JMT), and high-dose JMT (15.2 mg/kg) treated group (DPN + JMTH). The pharmacological effects of JMT on neurological function, neuropathology, and the levels of M1 and M2 macrophage cytokine markers were evaluated in serum and sciatic nerve, respectively. After chemical profiling of JMT by liquid chromatography coupled with high-resolution mass spectrometry, network pharmacology analysis was subsequently employed to predict the potential signaling pathways that JMT targeted in treating DPN. We further explored JMT’s neuroprotective effect in a second batch of in-vivo experiments. To do this, we co-administered the JAK2/STAT3 inhibitor AG490 along with macrophage polarizing agents: LPS and interleukin-4 (IL-4). The changes of M1 and M2 macrophages in bone marrow was investigated by cytometry, while the macrophages in sciatic nerves were observed by immunofluorescence. Myelin morphology was observed with Luxel fast blue staining and transmission electron microscopy. Immunofluorescence was performed to evaluate nerve injury and regeneration, with S100 and neurofilament 160 (NF160) used to label Schwann cells and axons respectively in the sciatic nerve. The protein expressions of JAK2/STAT3 signaling in sciatic nerves were examined by Western blot. Results: JMT significantly improved neurological function and pathological damage in type 2 DPN rats. Eight weeks after diabetes induction, DPN rats showed a significant increase in pro-inflammatory cytokines and a concurrent decrease in anti-inflammatory cytokines. JMT administration effectively restored the imbalance. Furthermore, JMT reduced the proportion of M1 macrophages while increasing that of M2 macrophages. JMT promoted the polarization of macrophages from the M1 to the M2 phenotype in both bone marrow-derived macrophages and those infiltrating the sciatic nerve, which was mediated through the suppression of abnormal activation of the JAK2/STAT3 signaling pathway. Conclusions: JMT promotes the polarization of macrophages from the M1 to M2 phenotype and alleviates neuroinflammation in T2DM rats with DPN, which is associated with inhibition of the JAK2/STAT3 signaling pathway. These findings highlight the neuroprotective potential of JMT through immunomodulatory mechanisms. Graphical


  • Open Access

    Cinnamaldehyde attenuates streptozocin-induced diabetic osteoporosis in a rat model by modulating netrin-1/DCC-UNC5B signal transduction

    by Songjie Ji, Bingjia Zhao, Yuan Gao, Jun Xie, Huijun Han, Qunli Wu, Dan Yang

    Background: Cinnamaldehyde (CMD) is a major functional component of Cinnamomum verum and has shown treatment effects against diverse bone diseases. This study aimed to assess the anti-diabetic osteoporosis (DOP) potential of diabetes mellitus (DM) and to explore the underlying mechanism driving the activity of CMD.Methods: A DOP model was induced via an intraperitoneal injection of streptozocin (STZ) into Sprague–Dawley rats, and then two different doses of CMD were administered to the rats. The effects of CMD on the strength, remodeling activity, and histological structure of the bones were assessed. Changes in the netrin-1 related pathways also were detected to elucidate the mechanism of the anti-DOP activity by CMD.Results: CMD had no significant effect on the body weight or blood glucose level of the model rats. However, the data showed that CMD improved the bone strength and bone remodeling activity as well as attenuating the bone structure destruction in the DOP rats in a dose-dependent manner. The expression of netrin-1, DCC, UNC5B, RANKL, and OPG was suppressed, while the expression of TGF-β1, cathepsin K, TRAP, and RANK was induced by the STZ injection. CMD administration restored the expression of all of these indicators at both the mRNA and protein levels, indicating that the osteoclast activity was inhibited by CMD.Conclusion: The current study demonstrated that CMD effectively attenuated bone impairments associated with DM in a STZ-induced DOP rat model, and the anti-DOP effects of CMD were associated with the modulation of netrin-1/DCC/UNC5B signal transduction.


  • Open Access

    Lentinan inhibits tumor angiogenesis via interferon γ and in a T cell independent manner

    by Shengming Deng, Guoxi Zhang, Jiajie Kuai, Peng Fan, Xuexiang Wang, Pei Zhou, Dan Yang, Xichen Zheng, Xiaomei Liu, Qunli Wu, et al.

    Background: Antiangiogenic agents are commonly used in lung and colon cancer treatments, however, rapid development of drug resistance limits their efficacy. Methods: Lentinan (LNT) is a biologically active compound extracted from Lentinus edodes. The effects of LNT on tumor angiogenesis were evaluated by immunohistochemistry in murine LAP0297 lung and CT26 colorectal tumor models. The impacts of LNT on immune cells and gene expression in tumor tissues were determined by flow cytometry, qPCR, and ELISA. Nude mice and IFNγ blockade were used to investigate the mechanism of LNT affecting on tumor angiogenesis. The data sets were compared using two-tailed student’s t tests or ANOVA. Results: We found that LNT inhibited tumor angiogenesis and the growth of lung and colon cancers. LNT treatments elevated the expression of angiostatic factors such as IFNγ and also increased tumor infiltration of IFNγ-expressing T cells and myeloid cells. Interestingly, IFNγ blockade, but not T cell deficiency, reversed the effects of LNT treatments on tumor blood vessels. Moreover, long-lasting LNT administration persistently suppressed tumor angiogenesis and inhibited tumor growth. Conclusions: LNT inhibits tumor angiogenesis by increasing IFNγ production and in a T cell-independent manner. Our findings suggest that LNT could be developed as a new antiangiogenic agent for long-term treatment of lung and colon cancers.